Xtant Medical Holdings, Inc. (XTNT) Form 8-K — May 13, 2026
Xtant Medical Holdings, Inc. reported a significant decline in revenue for the first quarter of 2026, with total revenue of $20.9 million, down from $32.9 million in the same period of 2025. This decline is primarily attributed to the sale of assets and businesses to Companion Spine in December 2025 and the cessation of 2025 license revenue. The company also announced a reduction in total indebtedness by $13.3 million in the first quarter of 2026, including a $10.4 million reduction in net amounts outstanding under its revolving line of credit and a $2.8 million reduction in its term loan balance.
Key figures
- Eps
- -0.02
- Revenue
- 20.9 million
- Net Income
- -3.1 million
- Total Debt
- 12.2 million
- Revenue Yoy
- -36.5%
- Cash And Equivalents
- 12.2 million
- Debt Reduction
- 13.3 million
- Revenue Guidance
- 101-105 million
- Previous Revenue Guidance
- 95-99 million
- HEMOBLASTRevenue Contribution
- not specified
Price after filing
Close on the filing date to close N calendar days later (from $0.48). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.